Trials / Unknown
UnknownNCT03268772
PLD and IFO As First-line Treatment for Patients With Advanced or Metastatic STS
Pegylated-liposome Doxorubicin Combined With Ifosfamide As First-line Treatment for Patients With Advanced or Metastatic Soft Tissue Sarcoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) combined with ifosfamide (IFO) for the first-line treatment of patients with advanced or metastatic soft tissue sarcoma (STS).
Detailed description
This phase II study is designed to evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) combined with ifosfamide (IFO) for the first-line treatment of patients with advanced or metastatic soft tissue sarcoma (STS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PLD and IFO | PLD 30 mg/m2, d1, plus IFO 1.8 g/m2, d1-5 |
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2020-11-30
- Completion
- 2020-12-30
- First posted
- 2017-08-31
- Last updated
- 2020-04-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03268772. Inclusion in this directory is not an endorsement.